PL3250610T3 - Przeciwciała anty-FcRn i sposoby ich stosowania - Google Patents
Przeciwciała anty-FcRn i sposoby ich stosowaniaInfo
- Publication number
- PL3250610T3 PL3250610T3 PL16744204.5T PL16744204T PL3250610T3 PL 3250610 T3 PL3250610 T3 PL 3250610T3 PL 16744204 T PL16744204 T PL 16744204T PL 3250610 T3 PL3250610 T3 PL 3250610T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- fcrn antibodies
- fcrn
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110071P | 2015-01-30 | 2015-01-30 | |
| US201562258082P | 2015-11-20 | 2015-11-20 | |
| PCT/US2016/015720 WO2016123521A2 (en) | 2015-01-30 | 2016-01-29 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3250610T3 true PL3250610T3 (pl) | 2024-01-29 |
Family
ID=56544538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16744204.5T PL3250610T3 (pl) | 2015-01-30 | 2016-01-29 | Przeciwciała anty-FcRn i sposoby ich stosowania |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10676526B2 (enExample) |
| EP (2) | EP3250610B1 (enExample) |
| JP (2) | JP6853178B2 (enExample) |
| KR (3) | KR102792441B1 (enExample) |
| CN (13) | CN113384693B (enExample) |
| AU (2) | AU2016211280B2 (enExample) |
| DK (1) | DK3250610T3 (enExample) |
| ES (1) | ES2962824T3 (enExample) |
| FI (2) | FIC20265011I1 (enExample) |
| FR (1) | FR26C1025I1 (enExample) |
| HR (1) | HRP20231399T1 (enExample) |
| HU (1) | HUE063778T2 (enExample) |
| IL (1) | IL252837B (enExample) |
| LT (2) | LT3250610T (enExample) |
| NL (1) | NL301379I2 (enExample) |
| NO (1) | NO2026027I1 (enExample) |
| NZ (1) | NZ772383A (enExample) |
| PL (1) | PL3250610T3 (enExample) |
| PT (1) | PT3250610T (enExample) |
| RS (1) | RS64768B1 (enExample) |
| SG (2) | SG10202007232WA (enExample) |
| SI (1) | SI3250610T1 (enExample) |
| SM (1) | SMT202300365T1 (enExample) |
| WO (1) | WO2016123521A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106103476B (zh) | 2013-12-24 | 2020-11-27 | 阿尔金克斯有限公司 | FcRn拮抗剂及使用方法 |
| US20170211876A1 (en) * | 2014-06-12 | 2017-07-27 | Hoffmann-La Roche Inc. | Method for selecting antibodies with modified fcrn interaction |
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| BR112019001806A2 (pt) * | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| MX2019015065A (es) * | 2017-06-15 | 2020-08-03 | UCB Biopharma SRL | Metodo para tratamiento de trombocitopenia inmunitaria. |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) * | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| IL280280B2 (en) * | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| JP7518821B2 (ja) | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| BR112021024632A2 (pt) | 2019-06-07 | 2022-01-18 | Argenx Bvba | Formulações farmacêuticas de inibidores de fcrn adequados para administração subcutânea |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| EP4061486A1 (en) * | 2019-11-19 | 2022-09-28 | Immunovant Sciences GmbH | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| CA3200972A1 (en) * | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| CN116782939A (zh) * | 2020-11-06 | 2023-09-19 | 动量制药公司 | FcRn抗体及其使用方法 |
| CN114410643B (zh) * | 2021-02-02 | 2024-08-02 | 百奥赛图(北京)医药科技股份有限公司 | FcRn基因人源化的非人动物及其构建方法和应用 |
| MX2023012032A (es) * | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| CN117693523A (zh) * | 2021-08-13 | 2024-03-12 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别fcrn的抗体及其用途 |
| CN116234827B (zh) * | 2021-09-03 | 2026-07-14 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| EP4658368A1 (en) | 2023-02-04 | 2025-12-10 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| IL328082A (en) | 2023-11-06 | 2026-06-01 | Momenta Pharmaceuticals Inc | Compositions and methods for treating rheumatoid arthritis |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2026083290A1 (en) | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2026136830A1 (en) * | 2024-12-20 | 2026-06-25 | Paragon Therapeutics, Inc. | Anti-fcrn antibodies and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| CA2534973A1 (en) * | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| CN101421297A (zh) * | 2006-02-17 | 2009-04-29 | 森托尼克斯制药有限公司 | 阻断lgG对FcRn的结合的肽 |
| WO2007104529A2 (en) * | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| US8273351B2 (en) * | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| CN102549016B (zh) * | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| BR112013030352B1 (pt) * | 2011-06-02 | 2020-05-19 | Dyax Corp. | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2991666B1 (en) | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| JP6853178B2 (ja) * | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| MX386491B (es) * | 2015-03-09 | 2025-03-18 | argenx BV | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. |
| CA3022547A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| BR112019001806A2 (pt) * | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| IL280280B2 (en) | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
-
2016
- 2016-01-29 JP JP2017539428A patent/JP6853178B2/ja active Active
- 2016-01-29 CN CN202110605791.0A patent/CN113384693B/zh active Active
- 2016-01-29 US US15/546,870 patent/US10676526B2/en active Active
- 2016-01-29 CN CN202410661144.5A patent/CN118562003A/zh active Pending
- 2016-01-29 NZ NZ772383A patent/NZ772383A/en unknown
- 2016-01-29 CN CN202410661140.7A patent/CN118667010A/zh active Pending
- 2016-01-29 SG SG10202007232WA patent/SG10202007232WA/en unknown
- 2016-01-29 SG SG11201705475QA patent/SG11201705475QA/en unknown
- 2016-01-29 HR HRP20231399TT patent/HRP20231399T1/hr unknown
- 2016-01-29 CN CN202410661149.8A patent/CN118667013A/zh active Pending
- 2016-01-29 CN CN202410661136.0A patent/CN118638230A/zh active Pending
- 2016-01-29 CN CN202410661131.8A patent/CN118638229A/zh active Pending
- 2016-01-29 CN CN202410661152.XA patent/CN118667015A/zh active Pending
- 2016-01-29 WO PCT/US2016/015720 patent/WO2016123521A2/en not_active Ceased
- 2016-01-29 LT LTEPPCT/US2016/015720T patent/LT3250610T/lt unknown
- 2016-01-29 ES ES16744204T patent/ES2962824T3/es active Active
- 2016-01-29 PL PL16744204.5T patent/PL3250610T3/pl unknown
- 2016-01-29 CN CN202410661147.9A patent/CN118667012A/zh active Pending
- 2016-01-29 EP EP16744204.5A patent/EP3250610B1/en active Active
- 2016-01-29 EP EP23189767.9A patent/EP4286011A3/en active Pending
- 2016-01-29 AU AU2016211280A patent/AU2016211280B2/en active Active
- 2016-01-29 SI SI201631739T patent/SI3250610T1/sl unknown
- 2016-01-29 CN CN201680008485.6A patent/CN107567460B/zh active Active
- 2016-01-29 FI FIC20265011C patent/FIC20265011I1/fi unknown
- 2016-01-29 CN CN202410661150.0A patent/CN118667014A/zh active Pending
- 2016-01-29 FI FIEP16744204.5T patent/FI3250610T3/fi active
- 2016-01-29 KR KR1020227045647A patent/KR102792441B1/ko active Active
- 2016-01-29 CN CN202410661138.XA patent/CN118652337A/zh active Pending
- 2016-01-29 KR KR1020177024165A patent/KR102483016B1/ko active Active
- 2016-01-29 RS RS20231028A patent/RS64768B1/sr unknown
- 2016-01-29 KR KR1020257010788A patent/KR20250052465A/ko active Pending
- 2016-01-29 CN CN202410661142.6A patent/CN118667011A/zh active Pending
- 2016-01-29 PT PT167442045T patent/PT3250610T/pt unknown
- 2016-01-29 SM SM20230365T patent/SMT202300365T1/it unknown
- 2016-01-29 DK DK16744204.5T patent/DK3250610T3/da active
- 2016-01-29 HU HUE16744204A patent/HUE063778T2/hu unknown
- 2016-01-29 CN CN202410661133.7A patent/CN118667009A/zh active Pending
-
2017
- 2017-06-11 IL IL252837A patent/IL252837B/en unknown
-
2020
- 2020-03-20 US US16/825,066 patent/US11732047B2/en active Active
-
2021
- 2021-01-12 JP JP2021002601A patent/JP7224382B2/ja active Active
-
2022
- 2022-02-21 AU AU2022201145A patent/AU2022201145B2/en active Active
-
2023
- 2023-07-13 US US18/351,827 patent/US20240158508A1/en active Pending
-
2026
- 2026-04-29 LT LTPA2026518C patent/LTPA2026518I1/lt unknown
- 2026-05-06 NL NL301379C patent/NL301379I2/nl unknown
- 2026-05-13 FR FR26C1025C patent/FR26C1025I1/fr active Active
- 2026-05-29 NO NO2026027C patent/NO2026027I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304117A (en) | Anti-pvrig antibodies and methods of use | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| PL3601358T3 (pl) | Przeciwciała anty-trem2 i sposoby ich wykorzystania | |
| IL271025A (en) | Multibiotic agents and methods of using the same | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| PL3215532T3 (pl) | Przeciwciała anty-TIM3 i sposoby ich zastosowania | |
| IL282048A (en) | Oxysterols and methods of use thereof | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| IL259713A (en) | Anti-dr5 antibodies and methods of use thereof | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| IL259495A (en) | Antibodies and methods for using them | |
| IL254887A0 (en) | Anti-sortilin antibodies and methods of using them | |
| IL249092A0 (en) | Anti-gitr antibodies and methods of use thereof | |
| IL254068A0 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| SI3303394T1 (sl) | Protitelesa proti-CTLA-4 in postopki njihove uporabe | |
| CL2016002462A1 (es) | Anticuerpos anti-ox40 y métodos de uso | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| PL3828194T3 (pl) | Oksysterole i sposoby ich stosowania | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| IL258627B (en) | Anti-htra1 antibodies and methods of using them | |
| IL254951B (en) | Humanized influenza monoclonal antibodies and methods of use thereof | |
| EP3630046C0 (en) | ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USE THEREOF | |
| IL313083A (en) | Tralipressin compounds and methods of using them |